ArticlemedRxiv : the preprint server for health sciences2025
Quantify the Contribution of Modifiable Risk Factors for Progression of MGUS to Multiple Myeloma.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
11 authors.
Funding
Abstract
backgroundMultiple myeloma (MM), the most common plasma cell dyscrasia in the U.S., is preceded by an asymptomatic precursor monoclonal gammopathy of undetermined significance (MGUS). Although several risk factors for MGUS progression are known, their relative contributions remain unclear. Unlike other malignancies, such evidence is lacking for MM despite its high burden.
objectiveTo quantify contributions of modifiable risk factors to MGUS progression to MM to inform prevention.
designRetrospective cohort study conducted from 1/1/2024-12/31/2024.
settingNationwide U.S. Veterans Health Administration (VHA).
participantsPatients with MGUS (IgG, IgA, or light chain) diagnosed from 10/1/1999-12/31/2023.
interventionsModifiable risk factors including excess body mass index (BMI), chemical exposure, and comorbidities. MEASUREMENTS: Excess body mass index was defined as BMI ≥25 kg/m2, chemical exposure was measured by prior exposure to Agent Orange, comorbidities were summarized using Charlson Comorbidity Index. Multivariable-adjusted population attributable fractions (aPAF) was calculated for each modifiable risk factor. The aPAF estimates the proportion of progression in patients diagnosed with MGUS that could have been prevented, if a given risk factor were absent.
resultsThe cohort included 35,073 MGUS patients (33,670 [96.0%] male and 23,218 [66.2%] White), of whom 2,895 (8.3%) progressed to MM. Median age at MGUS diagnosis was 71.8 (IQR: 64.4-78.6) years. Among all evaluated risk factors, excess BMI was the leading factor (Black: aPAF=27.1%, 95% CI 19.5-34.0%; White: 27.2%, 95% CI 20.3-33.4%; All: aPAF=27.1%, 95% CI: 22.1-31.9%). LIMITATIONS: Potential residual confounding, limited generalizability beyond the VHA population.
conclusionOur study highlights the potential for weight management as a key strategy in reducing the risk of progression to MM in Black and White patients diagnosed with MGUS. PRIMARY FUNDING SOURCE: National Institutes of Health.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.